Novartis AG (NVS)
Automate Your Wheel Strategy on NVS
With Tiblio's Option Bot, you can configure your own wheel strategy including NVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Novartis AG (NVS) Shareholder/Analyst Call Prepared Remarks Transcript
Published: March 06, 2026 by: Seeking Alpha
Sentiment: Neutral
Novartis AG (NVS) Shareholder/Analyst Call Prepared Remarks Transcript
Read More
Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU
Published: March 03, 2026 by: Zacks Investment Research
Sentiment: Positive
NVS wins CHMP backing for remibrutinib in chronic spontaneous urticaria, bringing its oral BTK inhibitor closer to EU approval.
Read More
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
Published: February 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
Adds Avidity's differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipeline Potentially unlocks multi-billion-dollar opportunities with planned product launches before 2030 Strengthens late-stage pipeline to further support 2025-2030 net sales CAGR of 5-6% cc and mid to long term growth outlook Basel, February 27, 2026 -- Novartis AG (NYSE: NVS) today announced that it has successfully completed its acquisition of Avidity Biosciences, Inc. (“Avidity”). With the completion of the acquisition, Avidity is now an indirect, wholly owned subsidiary of Novartis.
Read More
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
Published: February 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
Basel, February 27, 2026 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for remibrutinib. The opinion supports its use as an oral treatment for chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1‑antihistamine treatment. “The introduction of remibrutinib represents a major advancement, providing clinicians with an oral Bruton's tyrosine kinase inhibitor (BTKi) treatment, with improvements in symptoms observed as early as Week 1,” said Prof. Dr. med. Martin Metz, Deputy Director, Institute of Allergology, Charité Universitätsmedizin Berlin. …
Read More
Novartis, Genentech file suit alleging illegal importation of prescription drug
Published: February 26, 2026 by: CNBC
Sentiment: Negative
Novartis and Genentech are suing a U.S. company and a Canadian pharmacy over the importation of a Canadian version of their allergy medicine. The importation of the drug, which has strict shipping and temperature controls, potentially puts patients at risk, the suit said.
Read More
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
Published: February 23, 2026 by: GlobeNewsWire
Sentiment: Neutral
Basel, February 23, 2026 – Novartis will present data from five key abstracts evaluating the highly selective oral Bruton's tyrosine kinase inhibitor (BTKi) Rhapsido® (remibrutinib) in chronic spontaneous urticaria (CSU) and as an investigational therapy for peanut allergy at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, PA, from February 27 to March 2, 2026. These presentations provide more evidence on the use of Rhapsido in CSU, as well as its potential in other indications and highlight Novartis commitment to addressing unmet needs in patients with immune-mediated diseases. New analyses on the impact of Rhapsido …
Read More
Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades
Published: February 22, 2026 by: The Motley Fool
Sentiment: Neutral
Novartis is a large drugmaker with a wide-ranging portfolio. Like all drugmakers, it faces the challenge of patent expirations.
Read More
NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Novartis posts positive phase III ALIGN data for Vanrafia in IgAN, showing slower kidney decline as it eyes full approval in 2026.
Read More
Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
NVS tops Q4 EPS estimates as margins expand, but revenues miss the mark amid U.S. generics hitting Entresto and Promacta, reshaping its growth mix.
Read More
Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Why Novartis (NVS) is a Top Value Stock for the Long-Term
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Exploring Analyst Estimates for Novartis (NVS) Q4 Earnings, Beyond Revenue and EPS
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Novartis (NVS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
Novartis CEO on impact of 'most favored nation' drug pricing
Published: January 22, 2026 by: CNBC Television
Sentiment: Neutral
Novartis CEO Vas Narasimham, speaking with CNBC about lowering drug prices, said the focus should be on reducing patient out-of-pocket drug costs, not list or net prices, though believes progress is moving in the right direction.
Read More
Novartis CEO Vas Narasimhan: ‘We really should be talking about out-of-pocket costs' in the U.S.
Published: January 22, 2026 by: CNBC Television
Sentiment: Neutral
Vas Narasimhan, CEO of Novartis, joins 'Money Movers' to discuss U.S. drug pricing, healthcare, and more.
Read More
Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Positive
FDA grants Breakthrough Therapy status to NVS's ianalumab for Sjogren's disease with plans for global filings starting in 2026.
Read More
Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Neutral
Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.
Read More
Novartis (NVS) is a Top-Ranked Value Stock: Should You Buy?
Published: January 14, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Zonsen PepLib Biotech and Novartis Sign Worldwide License Agreement regarding Radioligand Therapy Asset
Published: January 13, 2026 by: Business Wire
Sentiment: Neutral
ZHUZHOU, China & BOSTON--(BUSINESS WIRE)--Zonsen PepLib Biotech Inc. (“PepLib”) today announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based asset in the field of radioligand therapies (RLTs). Under the agreement, Novartis has obtained an exclusive worldwide license and will be responsible for the development and commercialization activities for the asset. The asset has been developed internally by PepLib to date. Through this transaction.
Read More
Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 12, 2026 by: Seeking Alpha
Sentiment: Neutral
Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
Novartis eyes more bolt-on acquisitions, CEO says
Published: January 12, 2026 by: Reuters
Sentiment: Positive
Novartis will continue to do bolt-on deals and its capital allocation priorities remain unchanged, CEO Vasant Narasimhan said at a major industry conference that kicked off on Monday in San Francisco.
Read More
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
Published: January 09, 2026 by: GlobeNewsWire
Sentiment: Neutral
East Hanover, N.J., January 9, 2026 – Novartis, a leading global innovative medicines company, today announced plans to build its fourth US radioligand therapy (RLT) manufacturing facility in Winter Park, Florida. The built-for-purpose, state-of-the-art facility represents another milestone in the company's $23 billion US investment announced in April 2025, further expanding manufacturing capabilities to meet growing demand for these cutting-edge cancer treatments. Novartis is scaling US manufacturing to bring innovative medicines closer to patients, so treatments are researched, made, and delivered with greater speed, reliability, and access in the communities where people live. The new 35,000-square-foot facility in Winter Park, …
Read More
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
Published: January 09, 2026 by: GlobeNewsWire
Sentiment: Neutral
Basel, January 9, 2026 – Novartis, a leading global innovative medicines company, today announced plans to build its fourth US radioligand therapy (RLT) manufacturing facility in Winter Park, Florida. The built-for-purpose, state-of-the-art facility represents another milestone in the company's $23 billion US investment announced in April 2025, further expanding manufacturing capabilities to meet growing demand for these cutting-edge cancer treatments. Novartis is scaling US manufacturing to bring innovative medicines closer to patients, so treatments are researched, made, and delivered with greater speed, reliability, and access in the communities where people live. The new 35,000-square-foot facility in Winter Park, Florida, will …
Read More
Novartis and US government reach agreement on lowering drug prices in the US
Published: December 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Basel, December 19, 2025 – Novartis, a leading global innovative medicines company, today announced it has reached an agreement with the US government that aims to lower the price of innovative medicines in the US and support continued US investment in manufacturing, and research and development.
Read More
Novartis, Roche near US drug price deal, Bloomberg News reports
Published: December 17, 2025 by: Reuters
Sentiment: Positive
The White House is set to announce drug pricing deals with pharmaceutical heavyweights Novartis AG and Roche Holding AG as soon as Friday, Bloomberg News reported on Wednesday citing people familiar with the situation.
Read More
Here's Why Novartis (NVS) is a Strong Value Stock
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy Transcript
Published: December 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy Transcript
Read More
Here's Why Novartis (NVS) is a Strong Momentum Stock
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
FDA Greenlights Novartis' Gene Replacement Treatment for SMA
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA patient group.
Read More
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth
Published: November 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.
Read More
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts
Published: November 20, 2025 by: Benzinga
Sentiment: Positive
Novartis AG (NYSE: NVS) projects a stronger growth trajectory through 2030, lifting expectations for several key medicines and outlining a pipeline strategy it believes will sustain momentum well into the next decade.
Read More
About Novartis AG (NVS)
- IPO Date 1996-11-07
- Website https://www.novartis.com
- Industry Drug Manufacturers - General
- CEO Vasant Narasimhan
- Employees 75883